Bluebird bio reaffirms Carlyle deal as Ayrmid misses deadline
Bluebird has reaffirmed its support for a proposed acquisition after Ayrmid failed to deliver a binding offer by the extended deadline.
Bluebird has reaffirmed its support for a proposed acquisition after Ayrmid failed to deliver a binding offer by the extended deadline.
What's Your Reaction?
